Hui WAN, Tie Yong QİAN, Xiao Jing HU, Ci You HUANG, Wei Feng YAO

Correlation of Serum CCL3/MIP-1α Levels with Disease Severity in Postmenopausal Osteoporotic Females

Background: The pro-inflammatory protein chemokine cytokineligand 3 is well established as a vital regulator of bone resorption andosteoclast stimulation.Aims: To investigate if serum cytokine ligand 3 levels correlated withdisease severity in postmenopausal osteoporotic women.Study Design: Cross-sectional study.Methods: Eighty-two postmenopausal osteoporotic women, 76postmenopausal non-osteoporotic women, and 80 healthy womenof childbearing age were recruited. The total hip, femoral neck, andL1-L4 spine bone mineral density were assessed by dual-energyX-ray absorptiometry. Serum cytokine ligand 3 concentrations wereexamined using a commercial enzyme-linked immunosorbent assaykit. Serum inflammatory cytokine interleukin-6, tumor necrosis factoralpha,and the bone metabolic markers, carboxy-terminal crosslinkedand tartrate-resistant acid phosphatase 5b were also examined. Scoreson both the visual analogue scale and the Oswestry Disability Indexwere utilized to assess clinical severity.Results: Patients in the postmenopausal osteoporotic group hadsignificantly increased serum cytokine ligand 3 levels compared withthose in both the postmenopausal non-osteoporotic group (40.9±15.1pg/mL vs 24.2±8.7 pg/mL, p

PDF

___

Brincat SD, Borg M, Camilleri G, Calleja-Agius J. The role of cytokines in postmenopausal osteoporosis. Minerva Ginecol 2014;66:391-407.
Tella SH, Gallagher JC. Prevention and treatment of postmenopausal osteoporosis. J Steroid Biochem Mol Biol 2014;142:155-70.
Kawana K, Takahashi M, Hoshino H, Kushida K. Comparison of serum and urinary C-terminal telopeptide of type I collagen in aging, menopause and osteoporosis. Clin Chim Acta 2002;316:109-15.
Obrant KJ, Ivaska KK, Gerdhem P, Alatalo SL, Pettersson K, Väänänen HK. Biochemical markers of bone turnover are influenced by recently sustained fracture. Bone 2005;36:786-92.
Johansson H, Odén A, Kanis JA, McCloskey EV, Morris HA, Cooper C, et al. A metaanalysis of reference markers of bone turnover for prediction of fracture. Calcif Tissue Int 2014;94:560-7.
Vasikaran S, Eastell R, Bruyere O, Foldes AJ, Garnero P, Griesmacher A, et al. Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos Int 2011;22:391-420.
Wu Y, Lee JW, Uy L, Abosaleem B, Gunn H, Ma M. Tartrate-resistant acid phosphatase (TRACP 5b): a biomarker of bone resorption rate in support of drug development: modification, validation and application of the BoneTRAP kit assay. J Pharm Biomed Anal 2009;49:1203-12.
Hayman AR, Dryden AJ, Chambers TJ, Warburton MJ. Tartrate-resistant acid phosphatase from human osteoclastomas is translated as a single polypeptide. Biochem J 1991;277:631-4.
Hayman AR, Macary P, Lehner PJ, Cox TM. Tartrate-resistant acid phosphatase (Acp 5): identification in diverse human tissues and dendritic cells. J Histochem Cytochem 2001;49:675-684.
Teodorczyk-Injeyan JA, Triano JJ, McGregor M, McGregor M, Woodhouse L, Injeyan HS. Elevated production of inflammatory mediators including nociceptive chemokines in patients with neck pain: a cross sectional evaluation. J Manipulative Physiol Ther 2011;34:498-505.
Llorián-Salvador M, González-Rodríguez S, Lastra A, Fernández-García MT, Hidalgo A, Menéndez L, et al. Involvement of CC Chemokine Receptor 1 and CCL3 in Acute and Chronic Inflammatory Pain in Mice. Basic Clin Pharmacol Toxicol 2016;119:32- 40.
Iwamoto J, Takeda T, Sato Y, Uzawa M. Effects of alendronate on metacarpal and lumbar bone mineral density, bone resorption, and chronic back pain in postmenopausal women with osteoporosis. Clin Rheumatol 2004;23:383-9.
Fechtenbaum J, Cropet C, Kolta S, Horlait S, Orcel P, Roux C. The severity of vertebral fractures and health-related quality of life in osteoporotic postmenopausal women. Osteoporos Int 2005;16:2175-9.
Cockerill W, Lunt M, Silman AJ, Cooper C, Lips P, Bhalla AK, et al. Health-related quality of life and radiographic vertebral fracture. Osteoporos Int 2004;15:113-9.
Ohtori S, Akazawa T, Murata Y, Kinoshita T, Yamashita M, Nakagawa K, et al. Risedronate decreases bone resorption and improves low back pain in postmenopausal osteoporosis patients without vertebral fractures. J Clin Neurosci 2010;17:209-13.
Kukita T, Kukita A, Harada H, lijima T. Regulation of osteoclastogenesis by antisense oligodeoxynucleotides specific to zinc finger nuclear transcription factors Egr-1 and WT1 in rat bone marrow culture system. Endocrinology 1997;138:4384-9.
Kim MS, Magno CL, Day CJ, Morrison NA. Induction of chemokines and chemokine receptors CCR2b and CCR4 in authentic human osteoclasts differentiated with RANKL and osteoclast like cells differentiated by MCP-1 and RANTES. J Cell Biochem 2006;97:512-8.
Yoshie O, Imai T, Nomiyama H. Chemokines in immunity. Adv Immunol 2001;78:57- 110.
Zupan J, Jeras M, Marc J. Osteoimmunology and the influence of proinflammatory cytokines on osteoclasts. Biochem Med (Zagreb) 2013;23:43-63.
Charles JF, Nakamura MC. Bone and the innate immune system. Curr Osteoporos Rep 2014;12:1-8.
Fairbank JC, Pynsent PB. The Oswestry disability index. Spine (Phila Pa 1976) 2000;25:2940-52.
Hawker GA, Mian S, Kendzierska T, French M. Measures of adult pain: Visual Analog Scale for Pain (VAS Pain), Numeric Rating Scale for Pain (NRS Pain), McGill Pain Questionnaire (MPQ), Short-Form McGill Pain Questionnaire (SF-MPQ), Chronic Pain Grade Scale (CPGS), Short Form-36 Bodily Pain Scale (SF-36 BPS), and Measure of Intermittent and Constant Osteoarthritis Pain (ICOAP). Arthritis Care Res (Hoboken) 2011;63(Suppl 11):240-52
World Health Organization. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: report of a WHO Study Group. World Health Organ Tech Rep Ser 1994;843:1-129.
Fu R, Liu H, Zhao S, Wang Y, Li L, Gao S, et al. Osteoblast inhibition by chemokine cytokine ligand3 in myeloma-induced bone disease. Cancer Cell Int 2014;14:132.
Kukita T, Nomiyama H, Ohmoto Y, Kukita A, Shuto T, Hotokebuchi T, et al. Macrophage inflammatory protein-1 alpha (LD78) expressed in human bone marrow: its role in regulation of hematopoiesis and osteoclast recruitment. Lab Invest 1997;76:399-406.
Kawao N, Tamura Y, Horiuchi Y, Okumoto K, Yano M, Okada K, et al. The Tissue Fibrinolytic System Contributes to the Induction of Macrophage Function and CCL3 during Bone Repair in Mice. PLoS One 2015;10:e0123982.
Jämsen E, Kouri VP, Ainola M, Goodman SB, Nordström DC, Eklund KK, et al. Correlations between macrophage polarizing cytokines, inflammatory mediators, osteoclast activity, and toll-like receptors in tissues around aseptically loosened hip implants. J Biomed Mater Res A 2017;105:454-63.
Baba T, Mukaida N. Role of macrophage inflammatory protein (MIP)-1α/CCL3 in leukemogenesis. Mol Cell Oncol 2014;1:e29899.
Fu R, Liu H, Zhao S, Wang Y, Li L, Gao S, et al. Osteoblast inhibition by chemokine cytokine ligand3 in myeloma-induced bone disease. Cancer Cell Int 2014;14:132.
Legler DF, Thelen M. Chemokines: Chemistry, Biochemistry and Biological Function. Chimia (Aarau) 2016;70:856-9.
Eastell R, Hannon RA. Biomarkers of bone health and osteoporosis risk. Proc Nutr Soc 2008;67:157-62.
Shetty S, Kapoor N, Bondu JD, Thomas N, Paul TV. Bone turnover markers: Emerging tool in the management of osteoporosis. Indian J Endocrinol Metab 2016;20:846-52
Fan YL, Peh WC. Radiology of Osteoporosis: Old and New Findings. Semin Musculoskelet Radiol 2016;20:235-45.
Schweser KM, Crist BD. Osteoporosis: a discussion on the past 5 years. Curr Rev Musculoskelet Med 2017;10:265-74.
Chan CK, Mason A, Cooper C, Dennison E. Novel advances in the treatment of osteoporosis. Br Med Bull 2016;119:129-42.
Abrahamsen B, van Staa T, Ariely R, Olson M, Cooper C. Excess mortality following hip fracture: a systematic epidemiological review. Osteoporos Int 2009;20:1633-50.
Pietschmann P, Rauner M, Sipos W, Kerschan-Schindl K. Osteoporosis: an agerelated and gender-specific disease a mini-review. Gerontology 2009;55:3-12.
Compston J. Osteoporosis: advances in risk assessment and management. Clin Med (Lond) 2016;16(Suppl 6):121-24.
Pisani P, Renna MD, Conversano F, Casciaro E, Di Paola M, Quarta E, et al. Major osteoporotic fragility fractures: risk factor updates and societal impact. World J Orthop 2016;7:171-81.
Black DM, Rosen CJ. Clinical Practice. Postmenopausal Osteoporosis. N Engl J Med 2016;374:254-62.